PREMARIN (conjugated estrogens) Contraindications

Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

PREMARIN (conjugated estrogens sustained release tablets) is contraindicated in the following conditions:

  • Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
  • Liver dysfunction or disease as long as liver function tests have failed to return to normal.
  • Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer).
  • Endometrial hyperplasia.
  • Known, suspected, or past history of breast cancer.
  • Undiagnosed abnormal genital bleeding.
  • Known or suspected pregnancy (see WARNINGS AND PRECAUTIONS, Special Populations, Pregnant Women)
  • Active or past history of confirmed venous thromboembolism (such as deep venous thrombosis or pulmonary embolism) or active thrombophlebitis.
  • Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial infarction, coronary heart disease).
  • Partial or complete loss of vision due to ophthalmic vascular disease.
  • Known thrombophilic disorders (e.g. protein C, protein S, or antithrombin deficiency).
  • Migraine with or without aura